<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800068</url>
  </required_header>
  <id_info>
    <org_study_id>20-013358</org_study_id>
    <nct_id>NCT04800068</nct_id>
  </id_info>
  <brief_title>Expanded Access [Ga-68] PSMA-11 PET Imaging</brief_title>
  <official_title>Expanded Access [Ga-68] PSMA-11 PET Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <brief_summary>
    <textblock>
      In this expanded access IND study, Mayo Clinic in Rochester MN offers [Ga-68] PSMA-11 PET/CT&#xD;
      or PET/MR imaging to patients who meet criteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [Ga-68] PSMA-11 PET/CT and PET/MR imaging has been shown to allow for accurate detection of&#xD;
      metastatic prostate cancer at the time of initial diagnosis and staging of patients with&#xD;
      high-risk prostate cancer and at the time of biochemical recurrence. In addition, available&#xD;
      data show superiority of metastatic lesion detection with [Ga-68] PSMA-11 PET over&#xD;
      conventional imaging. This improved lesion detection has a direct impact on selection of&#xD;
      anti-cancer therapy and thus may improve patient outcomes.&#xD;
&#xD;
      Under expanded access IND, enrolled patients will receive a clinical [68Ga] PSMA-11 PET/CT or&#xD;
      PET/MR for evaluation of their cancer. Imaging exams must be deemed clinically indicated by a&#xD;
      referring provider. Patients will be responsible for the cost of the imaging exam. Access is&#xD;
      limited.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>[Ga-68] PSMA-11 PET/CT</intervention_name>
    <description>Imaging scan</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>[Ga-68] PSMA-11 PET/MR</intervention_name>
    <description>Imaging scan</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participant Groups&#xD;
&#xD;
        There are two participant groups; please refer to the inclusion details below:&#xD;
&#xD;
        Group 1: Untreated High-Risk prostate cancer group (must meet at least one of the following&#xD;
        inclusion criteria):&#xD;
&#xD;
          1. Serum prostate-specific antigen (PSA) concentration of 20 ng/mL or more&#xD;
&#xD;
          2. Pathologic criteria of International Society of Uropathology (ISUP) grade group 3-5&#xD;
             (ISUP grades 3-5 are equivalent to pathologic Gleason scores of 4+3, 8, 9 or 10)&#xD;
&#xD;
          3. Local staging of T3 or worse (Indicating that cancer has invaded into tissues outside&#xD;
             of the prostate gland, as seen at either CT or MRI)&#xD;
&#xD;
        Biochemically Recurrent prostate cancer group (must meet one of the criteria):&#xD;
&#xD;
          1. In patients who have undergone a prostatectomy, PSA &gt; 0.2 ng/ml on 2 consecutive tests&#xD;
&#xD;
          2. In patients who have undergone definitive prostate radiation, PSA rise â‰¥ 2 ng/mL above&#xD;
             the nadir PSA&#xD;
&#xD;
        Exclusion Criteria: Current exclusion criteria for both groups includes:&#xD;
&#xD;
          1. Patients unable to sign informed consent&#xD;
&#xD;
          2. Patient with a life expectancy less than 6 months&#xD;
&#xD;
          3. Additional exclusion criteria may be added based on demand&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Jessica Brunn</last_name>
    <phone>507-422-6025</phone>
    <email>brunn.jessica@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Johnson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials.</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Geoffrey Johnson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

